FDG-PET as a predictive biomarker for therapy with everolimus in metastatic renal cell cancer

The mTOR (mammalian target of rapamycin) inhibitor, everolimus, affects tumor growth by targeting cellular metabolic proliferation pathways and delays renal cell carcinoma (RCC) progression. Preclinical evidence suggests that baseline elevated tumor glucose metabolism as quantified by FDG-PET ([(18)...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Chen, James L, Appelbaum, Daniel E, Kocherginsky, Masha, Cowey, Charles L, Kimryn Rathmell, Wendy, McDermott, David F, Stadler, Walter M
Format: Artigo
Jezik:Inglês
Izdano: Blackwell Science Inc 2013
Teme:
Clinical Cancer Research
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC3799289/
https://ncbi.nlm.nih.gov/pubmed/24156027
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.102
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki